证券代码：000766 证券简称：通化金马 公告编号：2025-40 通化金马药业集团股份有限公司 第十一届董事会 2025 年第九次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会2025年第九次临时会议通知 于2025年11月11日以微信和电子邮件形式送达全体董事。 2.2025 年 11 月 12 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 二、董事会会议审议情况 1、审议并通过《关于续聘公司 2025 年度审计机构的议案》 经审议，同意续聘北京德皓国际会计师事务所（特殊普通合伙）担任公司 2025 年度审计机构，负责公司 2025 年度财务审计及内部控制审计等工作。详见同日公司 在巨潮资讯网披露的《关于拟续聘会计师事务所的公告》。 本议案已经董事会审计委员会全票审议通过。 表 ...

11月12日，通化金马涨5.38%，截至发稿，报29.21元/股，成交2.71亿元，换手率0.99%，总市值282.31 亿元。 资料显示，通化金马药业集团股份有限公司位于吉林省通化市二道江区金马路999号，成立日期1993年2 月26日，上市日期1997年4月30日，公司主营业务涉及药品的研发、生产和销售。主营业务收入构成 为：生化药59.27%，中成药40.56%，原料药0.10%，其他0.07%。 从通化金马十大流通股东角度 数据显示，华夏基金旗下1只基金位居通化金马十大流通股东。华夏中证1000ETF（159845）三季度新 进十大流通股东，持有股数525.31万股，占流通股的比例为0.54%。根据测算，今日浮盈赚取约782.71 万元。 华夏中证1000ETF（159845）成立日期2021年3月18日，最新规模454.69亿。今年以来收益27.98%，同 类排名1929/4216；近一年收益15.96%，同类排名2386/3937；成立以来收益28.76%。 华夏中证1000ETF（159845）基金经理为赵宗庭。 截至发稿，赵宗庭累计任职时间8年212天，现任基金资产总规模3558.65亿元，任 ...

Core Viewpoint - Tonghua Jinma's stock price has shown significant growth this year, with a year-to-date increase of 76.75%, despite a slight decline in the last five trading days [1][2]. Financial Performance - For the period from January to September 2025, Tonghua Jinma reported operating revenue of 892 million yuan, a year-on-year decrease of 7.88%, while the net profit attributable to shareholders increased by 4.35% to 24.96 million yuan [2]. - The company has cumulatively distributed 210 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of November 11, 2023, Tonghua Jinma's stock was trading at 27.75 yuan per share, with a market capitalization of 26.82 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent net purchase of 142 million yuan on September 11 [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders was 38,200, a decrease of 3.20% from the previous period, with an average of 25,266 circulating shares per shareholder, an increase of 3.31% [2][3]. - Notable shareholders include Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings compared to the previous period [3].

Group 1 - Company plans to raise no more than 3.6 billion yuan through a private placement to fund seven projects, including a 500,000 kW green power project in Inner Mongolia [1] - Company has received acceptance for a clinical trial application for its self-developed drug for metastatic pancreatic ductal adenocarcinoma [1] - Company intends to establish a joint venture to implement a high-quality gallium arsenide chip construction project with a total investment of 272 million yuan [2] Group 2 - Company reported a revenue of 142 million yuan from pig sales in October, with a total sales volume of 162,800 pigs [3] - Company signed an annual procurement contract to supply 870,000 tons of electrolyte products from 2026 to 2028 [5] - Company plans to reduce its shareholding by up to 3% through various trading methods [7] Group 3 - Company intends to purchase 100 hydrogen fuel cell vehicles for a total price of 78.32 million yuan [9] - Company plans to acquire a 51% stake in a semiconductor equipment company for 510 million yuan [10] - Company has regained eligibility to participate in military procurement activities after being removed from the banned list [12] Group 4 - Company plans to establish a joint venture with state-owned funds for rural development with a total registered capital of 2.87 billion yuan [14] - Company reported a revenue of 1.918 billion yuan from pig sales in October, with a significant year-on-year increase [16][17] - Company plans to distribute a cash dividend of 0.01 yuan per share, totaling 7.9801 million yuan [18] Group 5 - Company has submitted an application for H-share listing on the Hong Kong Stock Exchange [19] - Company received approval for its convertible bond issuance application [20] - Company plans to establish a wholly-owned subsidiary with an investment of 70 million yuan focused on innovative medical research [22] Group 6 - Company reported a 33.87% year-on-year increase in sales volume for October [26] - Company has received a product designation from a leading new energy vehicle brand, with an expected total revenue of approximately 470 million yuan [28] - Company has initiated a key Phase III clinical trial for an innovative eye drop treatment for moderate to severe dry eye syndrome [30] Group 7 - Company reported a total automobile sales volume of 170,700 units in October, a year-on-year decrease of 8.1% [30] - Company plans to invest 16 million USD in establishing a production base in Vietnam [33] - Company has received a warning letter from the regulatory authority due to a breach of commitment by its controlling shareholder [52]

Core Viewpoint - Tonghua Jinma announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million RMB to support its overall strategic planning and R&D needs [2] Group 1: Company Announcement - The company held the 8th temporary meeting of the 11th board of directors on November 6, 2025, to review the proposal for the establishment of the subsidiary [2] - The investment will be funded through the company's own or self-raised funds [2]

Group 1 - The company announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million yuan to support its strategic planning and R&D needs [1][3] - The company operates in various fields including oncology, microbiology, cardiovascular, detoxification, digestive system, musculoskeletal system, gynecology, and neurology [1] - The R&D process is managed by the headquarters, with production bases conducting projects based on their characteristics and market layout, including both innovative and generic drug development [1] Group 2 - The company received a notice of acceptance for the market application of Amber Dihydroaminoacridine Tablets, a new drug for treating mild to moderate Alzheimer's disease, which has undergone extensive clinical trials since 2007 [2] - The company emphasizes that new drug development is a long-term, high-investment, and high-tech process, with uncertainties regarding market prospects and economic returns [2] - The establishment of the subsidiary is part of the company's strategy to transform into an innovation-driven modern pharmaceutical enterprise, enhancing its core competitiveness and ensuring sustainable development [3]

Core Viewpoint - Tonghua Golden Horse plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to enhance its strategic focus on innovation-driven development in the pharmaceutical industry [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own or raised funds [1] - The establishment of the subsidiary aligns with the company's strategy to transform into an innovation-driven modern pharmaceutical enterprise [1] - The move aims to strengthen the company's capabilities in mergers and acquisitions within the innovative drug sector, thereby enhancing its core competitiveness [1] Group 2: Long-term Sustainability - The initiative is intended to inject new momentum into the company's long-term sustainable development [1]

Core Viewpoint - Tonghua Jinma (000766) announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million yuan to support its strategic shift towards becoming an innovation-driven modern pharmaceutical enterprise [1] Group 1 - The investment of 70 million yuan will be funded through the company's own or raised funds [1] - The establishment of the subsidiary is part of the company's strategy to enhance its mergers and acquisitions and layout in the innovative drug industry [1] - This move aligns with the company's overall strategic planning and research and development needs [1]

Core Viewpoint - Tonghua Golden Horse (000766.SZ) plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to support its strategic shift towards becoming an innovation-driven modern pharmaceutical enterprise [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own or raised funds [1] - The establishment of the subsidiary is aimed at enhancing the company's capabilities in mergers and acquisitions within the innovative pharmaceutical industry [1] - This move is part of the company's long-term strategy to boost its core competitiveness and ensure sustainable development [1]

Core Viewpoint - Tonghua Golden Horse (000766.SZ) plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to support its strategic shift towards becoming an innovation-driven modern pharmaceutical enterprise [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own funds or raised funds [1] - The establishment of the subsidiary is aligned with the company's strategy to enhance its capabilities in the innovative drug industry through mergers and acquisitions [1] - This move aims to strengthen the company's core competitiveness and inject new momentum into its long-term sustainable development [1]